$541.00 - $7,325.00

$541.00 - $7.00

Choose an Option...
  • 25 mg - $7,325.00
  • 5 mg - $2,097.00
  • 1 mg - $541.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

The 29F.1A12™-CP005 monoclonal antibody is a recombinant chimeric version of the original 29F.1A12™ antibody. The variable domain sequences are identical to the original 29F.1A12™ but the constant region sequences have been switched from rat IgG2a to mouse IgG1. The 29F.1A12™-CP005 antibody also contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. 29F.1A12™-CP005 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

Specifications

Isotype Mouse IgG1, κ
Recommended Isotype Control(s) RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Mutations D265A
Immunogen Recombinant PD-1-Ig fusion protein
Reported Applications in vivo blocking of PD-1/PD-L signaling*
in vitro PD-1 neutralization*
Immunohistochemistry (frozen)*
Immunofluorescence*
Western blot*
Flow cytometry*
*Reported for the original rat IgG2a 29F.1A12 antibody
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL gel clotting assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from HEK293 cell supernatant in an animal-free facility
Purification Protein G
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Product FAQs

Related Products

  1. Catalog #CP162
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  2. Catalog #CP157
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  3. Catalog #CP151
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  4. Catalog #SIM0010
    InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) Read more
  5. Catalog #SIM0003
    InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) Read more
  6. Catalog #BP0273
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  7. Catalog #BE0273
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  8. Catalog #BP0146
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  9. Catalog #BP0033-2
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  10. Catalog #BE0146
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  11. Catalog #BE0033-2
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  12. Catalog #BE0193
    InVivoMAb anti-human PD-1 (CD279) Read more
  13. Catalog #BE0188
    InVivoMAb anti-human PD-1 (CD279) Read more
  14. Catalog #CP159
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  15. Catalog #CP153
    RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) Read more
  16. Catalog #CP002
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  17. Catalog #CP004
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  18. Catalog #CP165
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  19. Catalog #CP155
    RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) Read more
  20. Catalog #SIM0037
    InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar) Read more
  21. Catalog #SIM0038
    InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) Read more

Additional Formats

  1. Catalog #BE0273
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  2. Catalog #BP0273
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  3. Catalog #CP155
    RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) Read more
  4. Catalog #CP159
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  5. Catalog #CP178
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  6. Catalog #FM0273-APC
    FlowMAb APC anti-mouse PD-1 (CD279) Read more
  7. Catalog #FM0273-FITC
    FlowMAb FITC anti-mouse PD-1 (CD279) Read more
  8. Catalog #FM0273-PE
    FlowMAb PE anti-mouse PD-1 (CD279) Read more